Wilson Sonsini Goodrich & Rosati has advised Oak Hill Bio on patent matters related to the transaction. Oak Hill Bio, a clinical-stage rare disease therapeutics company,...
Oak Hill Bio Raises $32.5 Million in Series A Financing
GSK Acquires Worldwide License for Empirico’s COPD Candidate EMP-012
Wilson Sonsini Goodrich & Rosati has advised Empirico, and Davis Polk & Wardwell has advised GSK. GSK plc and Empirico Inc. have entered into a worldwide...
Predicta Biosciences Completes $23.4 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati has advised Predicta Biosciences. Predicta Biosciences, a precision oncology company focused on developing novel diagnostic and therapeutic discovery solutions, has announced...
Enlaza and Vertex Pharmaceuticals Enter Multi-Target Drug Discovery Collaboration
Cooley and Wilson Sonsini Goodrich & Rosati have advised Enlaza Therapeutics, and Covington has advised Vertex Pharmaceuticals. Enlaza Therapeutics has entered into a multi-target drug discovery...
Oak Hill Bio’s License Agreement with Roche
Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction. Oak Hill Bio, a biotechnology company focused on acquiring and...
Aadi Bioscience’s $849 Million ADC Deal, $100 Million FYARRO Sale and $100 Million PIPE Financing
Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Aadi. McDermott Will & Emery LLP is serving as legal counsel to Kaken. Cooley...
Enlaza Therapeutics’ $100 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction. Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it closed...
Belite Bio’s $36 Million IPO
Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal. Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of...